Novartis CEO's statin? Pfizer's Lipitor

What's a pharma CEO with high cholesterol to do? Take his company's statin, of course. But Novartis chief Daniel Vasella (photo) eschews Lescol in favor of... Pfizer's Lipitor. Vasella tried Lescol. Twice. But side effects pushed him off the drug and onto Lipitor.

As the Wall Street Journal's Health Blog notes, Vasella's experience is just one of the many times Lescol has lost out. Viewed as less potent than other statins, Lescol totes up global sales of less than $1 billion, compared with $10 billion for Lipitor. And both now are losing out to Zocor imitators.

- check out the item from the Health Blog

Related Articles:
Sleep study could boost some statins. Report
Switching to generic statins not so healthy. Report

Suggested Articles

Despite having lost some of its novelty, AZ's Brilinta is touting bleeding data over aspirin that could be a big break in acute coronary syndrome.

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Having already whiffed on one crucial heart failure trial, Novartis is focusing on "profound" data from its Entresto studies in hopes for another go.